No Data
No Data
Needham Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Maintains Target Price $2.5
Lucid Diagnostics Gains Buy Rating Amidst Clinical and Commercial Advancements
Express News | Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (Nccn) Guidelines Now Include Esophageal Precancer Screening
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network (NCCN) Guidelines Now Include Esophageal Precancer Screening
Earnings Preview: LUCD to Report Financial Results Pre-market on March 24
$Lucid Diagnostics(LUCD.US)$ is scheduled to release its financial results pre-market on March 24 ET. Earnings PreviewAnalysts estimate $Lucid Diagnostics(LUCD.US)$ to post revenue of USD1.42M for 202
BTIG Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Maintains Target Price $2.5
Unlock the Full List